Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Neurocrine's Ingrezza Fails Phase 3 Trial in Cerebral Palsy, Company Shifts Focus to Other Pipeline Assets

Neurocrine Biosciences faced a setback in its clinical development program as its drug Ingrezza (valbenazine) failed to meet primary and key secondary endpoints in a phase 3 trial for patients with dyskinesia due to cerebral palsy (CP). The announcement comes just days after the company's upbeat R&D event, highlighting the unpredictable nature of pharmaceutical research.

NoahAI News12/24/2025

William Blair's Top Biotech Stock Picks for 2026 Reveal Promising Developments in Neurology, Oncology, and Immunology

Investment firm William Blair has unveiled its top five biotech stock recommendations for 2026, highlighting potential breakthroughs in neurological disorders, cancer treatments, and inflammatory diseases. The selections, which include three clinical-stage biotechs, offer insights into the most promising areas of pharmaceutical development for the coming years.

NoahAI News12/24/2025

Stem Cell Therapy Shows Promise in Parkinson's Disease Phase 2 Trial

Hope Biosciences has reported encouraging results from a phase 2 clinical trial of its stem cell therapy for Parkinson's disease, potentially paving the way for a phase 3 study. The trial, which evaluated an allogeneic adipose-derived mesenchymal stem cell therapy, demonstrated significant improvements in motor function among treated patients.

NoahAI News12/24/2025

AstraZeneca Extends Radioisotope Supply Deal, Signaling Growing Interest in Radiopharmaceuticals

AstraZeneca has reinforced its commitment to radiopharmaceutical development by extending its supply agreement with Niowave, a Michigan-based medical radioisotope producer, for an additional 10 years. The deal focuses on the delivery of Actinium-225 (Ac-225), a promising radioisotope for targeted cancer therapy.

NoahAI News12/24/2025

Patient Death Reported in Pfizer's Long-Term Hympavzi Trial for Hemophilia A

Pfizer, the New York-based pharmaceutical giant, disclosed on Monday that a patient participating in a long-term follow-up clinical trial of its approved hemophilia A therapy, Hympavzi, has died. The incident marks a significant development in the ongoing evaluation of the drug's safety profile and could potentially impact its market position.

NoahAI News12/23/2025

Hope Biosciences Reports Promising Phase 2 Results for Parkinson's Stem Cell Therapy

Hope Biosciences has announced encouraging results from its phase 2 trial of an allogeneic adipose-derived mesenchymal stem cell therapy for Parkinson's disease. The study, which involved 60 patients with early to moderate Parkinson's, showed significant improvements in motor function as measured by clinician assessments.

NoahAI News12/23/2025

AstraZeneca Extends Radioisotope Supply Deal, Signaling Growth in Radiopharmaceuticals

AstraZeneca, a leading pharmaceutical giant, has significantly expanded its commitment to radiopharmaceutical development by extending its supply agreement with Niowave, a Michigan-based medical radioisotope producer. The new 10-year deal focuses on the delivery of Actinium-225 (Ac-225), a promising radioisotope for targeted cancer therapy.

NoahAI News12/23/2025

Radiopharmaceutical Biotech Aktis Oncology Files for IPO, Signaling Potential Industry Rebound

Aktis Oncology, a radiopharmaceutical specialist backed by major pharmaceutical companies, has filed for an initial public offering (IPO), marking the first biotech IPO filing in several weeks. This move comes amid signs of a broader recovery in the biotech sector, potentially heralding a resurgence of IPO activity in 2026.

NoahAI News12/23/2025

FDA Scrutiny Impacts Disc Medicine's Bitopertin Review, Raising Questions About CNPV Program

Disc Medicine's shares took a hit following reports that FDA biologics center director Vinay Prasad has expressed skepticism about the efficacy of bitopertin, the company's candidate for treating the rare blood disorder porphyria. This development has brought attention to the Commissioner's National Priority Voucher (CNPV) program and its impact on drug review timelines.

NoahAI News12/23/2025

AstraZeneca's ATR Inhibitor Falls Short in Phase III Lung Cancer Trial

AstraZeneca faced a setback in its ambitious growth plans as its investigational ATR kinase inhibitor, ceralasertib, failed to improve overall survival in a Phase III clinical trial for non-small cell lung cancer (NSCLC). The late-stage LATIFY trial, which combined ceralasertib with AstraZeneca's blockbuster immunotherapy drug Imfinzi (durvalumab), did not meet its primary endpoint when compared to standard-of-care chemotherapy in patients with advanced or metastatic disease.

NoahAI News12/23/2025

AstraZeneca Expands Chinese Footprint with $2B KRAS Inhibitor Deal

AstraZeneca has further solidified its presence in China's pharmaceutical landscape, announcing a potentially $2 billion deal with Jacobio Pharma for the development of a novel pan-KRAS inhibitor. This latest move underscores the growing importance of China in global drug discovery and development efforts.

NoahAI News12/23/2025

Cytokinetics' Myqorzo Wins FDA Approval, Setting Stage for Heart Disease Market Battle with Bristol Myers Squibb

In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval to Cytokinetics' cardiac myosin inhibitor, Myqorzo (aficamten), for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This approval, announced on December 22, 2025, marks a significant milestone for Cytokinetics, representing the company's first FDA-approved product in its nearly three-decade history.

NoahAI News12/23/2025

«1 2 3 4...67 »